To improve adherence and care management for people living with COPD and asthma, Propeller Health today announced it will partner with global pharmaceutical company Boehringer Ingelheim.

“We are excited to work with Boehringer Ingelheim to bring Propeller to people with asthma and COPD at health systems across the United States,” Propeller CEO David Van Sickle said in a statement. “Together, we believe that digital tools can complement the use of respiratory medications and encourage more appropriate and effective management of chronic respiratory disease.”

According to a release, people living with COPD and asthma who are being treated with a Boehringer Ingelheim prescription medication approved for use in the company’s RESPIMAT inhaler can have the opportunity to enroll at select U.S. health systems in a new program that is designed to figure out how Propeller’s health technology tool impacts adherence rates and patient engagement.

To date, Propeller’s products have been used by people with respiratory diseases in more than 40 commercial programs across the country.